Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women
Latest Information Update: 06 May 2022
Price :
$35 *
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms VOICE
- 26 Apr 2022 Results of a pooled participant-level data analysis ((iPrEx, VOICE and Partners PrEP studies) characterizing HIV-preventive, plasma tenofovir concentrations published in the Clinical Infectious Diseases
- 16 Feb 2022 Results assessing vaginal proteins that associate with HIV acquisition in women enrolled in the VOICE trial presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 24 Aug 2020 Results of a comprehensive model analysis using data from following clinical studies: HPTN082, VOICE trial, HPTN035, FEM-PrEP, ASPIRE, ECHO trials for estimation of HIV incidences and interventions effectiveness published in the JAIDS